摘要
目的探讨多发性骨髓瘤(MM)患者血清β2-微球蛋白(β2-MG)和乳酸脱氢酶(LDH)检测的临床意义。方法分别采用速率法和放免法检测36例MM患者血清β2-MG和LDH值。结果正常组与MM组,I期与Ⅱ期,Ⅱ期与Ⅲ期,A组与B组以及化疗有效与无效患者间β2-MG及LDH相比,后组患者血清β2-MG和LDH水平均明显高于前组,差异有统计学意义(P<0.05),而无效组化疗前后差异无统计学意义(P>0.05)。结论血清β2-MG和LDH水平可作为患者分期、预后及疗效判断的辅助指标。
Objective To investigate the clinical significance of the serumβ2 -microglobulin （β2 -MG） and lactic dehydrogenase （LDH） measurrnent in patients with multiple myeloma, Methods 36 patients with multiple myeloma were enrolled in this study. β2 - MG and LDH were measured by rate method and radioimmunoassay, respectively. Results Patients were classified into phase Ⅰ or phase Ⅱ or phase Ⅲ, group A or group B, responsive to or unresponsive to chemotherapy group for comparison purese. It was found that value of β2 - MG and LDH for patients in the later categories were significantly higher than those in the former categories（ e, g. phase Ⅱ 〉 phase Ⅰ , phase Ⅲ 〉 phase Ⅱ） （ P 〈 0.05 ）. The differences before and after chemotherapy for unresponsive to chemotherapy group were not significant （ P 〉 0. 05 ）. Conclusion Serum level of β2 - MG and LDH can be used as an auxiliary clinical index for the determination of disease phases, prognosis and treatment effectiveness in patients with multiple myeloma.
出处
《临床和实验医学杂志》
2006年第12期1913-1914,共2页
Journal of Clinical and Experimental Medicine
关键词
多发性骨髓瘤
Β2-MG
LDH
β2 - micreglobulin
Lactic dehydrogenase
Multiple myeloma
